AIM: To examine the expression of thymidylate synthase (TS) and oncoprotein Bcl-2 in advanced colorectal cancer (CRC) patients, and to determine their mutual relationship, association to therapeutic response and impact on disease outcome. METHODS: Tumor samples from 67 patients with CRC, who were treated at advanced stage with either irinotecan alone or in combination with 5-fluorouracil/leucovorin, were analyzed for expression of TS and Bcl-2 using immunohistochemistry. RESULTS: A significant linear correlation between lower expression levels of Bcl-2 and lower levels of TS expression was found (P = 0.033). Patients with high levels of both TS and Bcl-2 expression had a significantly longer disease-free survival (DFS) (42.6 mo vs 5.4 mo, n = 25) than those with low TS/Bcl-2 index (P = 0.001). Tumors with low levels of both TS and Bcl-2 were associated with a longer survival with metastasis (WMS) interval in the whole patients group (n = 67, P = 0.035). TS/Bcl-2 index was not significantly related to disease-specific survival. CONCLUSION: The present data suggest that CRC patients with low TS/Bcl-2 demonstrate a significantly shorter DFS and longer WMS.
AIM: To examine the expression of thymidylate synthase (TS) and oncoprotein Bcl-2 in advanced colorectal cancer (CRC) patients, and to determine their mutual relationship, association to therapeutic response and impact on disease outcome. METHODS: Tumor samples from 67 patients with CRC, who were treated at advanced stage with either irinotecan alone or in combination with 5-fluorouracil/leucovorin, were analyzed for expression of TS and Bcl-2 using immunohistochemistry. RESULTS: A significant linear correlation between lower expression levels of Bcl-2 and lower levels of TS expression was found (P = 0.033). Patients with high levels of both TS and Bcl-2 expression had a significantly longer disease-free survival (DFS) (42.6 mo vs 5.4 mo, n = 25) than those with low TS/Bcl-2 index (P = 0.001). Tumors with low levels of both TS and Bcl-2 were associated with a longer survival with metastasis (WMS) interval in the whole patients group (n = 67, P = 0.035). TS/Bcl-2 index was not significantly related to disease-specific survival. CONCLUSION: The present data suggest that CRCpatients with low TS/Bcl-2 demonstrate a significantly shorter DFS and longer WMS.
Authors: H J Lenz; K Hayashi; D Salonga; K D Danenberg; P V Danenberg; R Metzger; D Banerjee; J R Bertino; S Groshen; L P Leichman; C G Leichman Journal: Clin Cancer Res Date: 1998-05 Impact factor: 12.531
Authors: T Yamachika; H Nakanishi; K Inada; T Tsukamoto; T Kato; M Fukushima; M Inoue; M Tatematsu Journal: Cancer Date: 1998-01-01 Impact factor: 6.860
Authors: L Leichman; H J Lenz; C G Leichman; S Groshen; K Danenberg; J Baranda; C P Spears; W Boswell; H Silberman; A Ortega Journal: Eur J Cancer Date: 1995 Jul-Aug Impact factor: 9.162
Authors: P G Johnston; E R Fisher; H E Rockette; B Fisher; N Wolmark; J C Drake; B A Chabner; C J Allegra Journal: J Clin Oncol Date: 1994-12 Impact factor: 44.544
Authors: P G Johnston; H J Lenz; C G Leichman; K D Danenberg; C J Allegra; P V Danenberg; L Leichman Journal: Cancer Res Date: 1995-04-01 Impact factor: 12.701
Authors: Shahad W Kattan; Yahya H Hobani; Nouf Abubakr Babteen; Saleh A Alghamdi; Eman A Toraih; Afaf T Ibrahiem; Manal S Fawzy; Salwa Faisal Journal: J Clin Lab Anal Date: 2022-01-07 Impact factor: 2.352